Acute Care Therapeutics for Surgical Settings

Baudax Bio is a pharmaceutical company focused on developing and commercializing innovative products for acute care settings.

About Baudax Bio

We are committed to bringing meaningful therapeutic options to patients, healthcare providers, and payers.  We currently have multiple therapeutic candidates across early, mid and late-stage clinical development, including a FDA approved non-opioid therapy for use in the acute care setting.

About Us

Our Innovative Portfolio & Pipeline

On February 20, 2020, the FDA approved ANJESO (meloxicam) injection, for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics.  Our product pipeline contains valuable therapeutic candidates for patients and healthcare providers in acute care settings.

ANJESO (meloxicam) injection

Product Portfolio

Latest News

Baudax Bio Announces Positive Outcome of Interim Analysis of Phase II Randomized Trial for BX1000

View Press Release

Baudax Bio Announces Positive Outcome of Interim Analysis of Phase II Randomized Trial for BX1000

View Press Release

Baudax Bio Initiates Phase II Clinical Trial Evaluating BX1000 in Patients Undergoing Surgery

View Press Release

Baudax Bio Announces Closing of $5 Million Public Offering

View Press Release

Baudax Bio Announces Pricing of $5 Million Public Offering

View Press Release

Baudax Bio Announces 1-for-40 Reverse Stock Split

View Press Release

Baudax Bio Reports Third Quarter 2022 Financial Results and Business Highlights

View Press Release

Baudax Bio Announces Distribution of Series B Preferred Stock to Holders of its Common Stock

View Press Release

Baudax Bio to Present at the 24th Annual H.C. Wainwright Healthcare Conference

View Press Release

Baudax Bio Announces Closing of $6.2 Million Public Offering

View Press Release

Email Alerts

Stay informed and receive company updates straight to your inbox.

Sign up today